Recombinant activated coagulation factor VII in the treatment of massive obstetric hemorrhage (literature review)
https://doi.org/10.21518/2079-701X-2014-9-68-75
Abstract
Back in 1630, Shah Jahan built the famous Taj Mahal Palace in the memory of his wife Mumtaz who died as a result of postpartum massive bleeding giving birth to her fourteenth child. [1] To this day, bleeding continues to be one of the most common obstetric complications. Massive life-threatening coagulopathic bleeding with blood loss more than 1.5% of body weight, or more than 30% of the circulating blood volume, is given special attention.
About the Authors
T. A. Fedorova
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov
Russian Federation
Russian Federation
E. V. Strelnikova
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov
Russian Federation
Russian Federation
References
1. Magon N. Editorial. Post partum hemorrhage: Can recombinant activated factor VII become the Brahma-Astra in Quiver? IntJ Clin Cases Investig, 2011, 3: 1-4.
2. Курцер М.А., Панин А.В. Сущевич Л.В. Перевязка внутренних подвздошных артерий как альтернатива гистерэктомии при массивных акушерских кровотечениях. Акуш. и гинек, 2005, 5: 12-15.
3. B-Lynch CB, Coker A, Laval AH et. al. The B-Lynch surgical technique for control of massive postpartum hemorrhage. аn Alternative to hysterectomy? Five cases reported. Br. J. Obstet. Gynecol., 1997, 104: 372.
4. Серов В.Н., Соколова Ю.Ю., Федорова Т.А., Фомин М.Д., Соколов В.А., Рогачевский О.В. Инфузионно-трансфузионная терапия кровопотери в акушерской практике. Акуш.и гин, 2005, 6: 14-17.
5. Say L et al. WHO systematic review of maternal morbidity and mortality: the prevalence of severe acute maternal morbidity (near miss). Reproductive Health, 2004, 1: 3.
6. Habek D, Be arevi R. Emergency Peripartum Hysterectomy in a Tertiary Obstetric Center: 8-Year Evaluation. FetalDiagn Ther, 2007, 22: 139-142.
7. Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Ezra Y, Levy I, Mazor M, Martinowitz U. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet, 2003, 268: 266-267.
8. Scarpelini S, Nascimento B, Tien H, Netto FACS, Tremblay L, Rizoli S. Overview on the use of recombinant factor VIIa in obstetrics and gynecology Expert Rev. Obstet. Gynecol, 2007, 2(2): 217-226.
9. Ghorashian S, Hunt BJ. Off-license use of recombinant activated factor VII. Elsevier Blood Reviews, 2004, 18: 245-259.
10. Logan AC, Yank V, Stafford RS Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med, 2011, 154(8): 516522.
11. Johansson PI. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang, 2008, 95(1): 1-7.
12. Зоренко В.Ю., Полянская Т.Ю., Галстян ГМ., Сампиев М.С., Северова Т.В., Коняшина Н.И., Орел Е.Б., Грибкова И.В., Алексанян М.Ж. Опыт применения препарата Коагил-VII при ортопедических операциях у больных с ингибиторной гемофилией А. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии, 2011, 10(3): 35-40.
Review
For citations:
Fedorova TA, Strelnikova EV. Recombinant activated coagulation factor VII in the treatment of massive obstetric hemorrhage (literature review). Meditsinskiy sovet = Medical Council. 2014;(9):68-75. (In Russ.) https://doi.org/10.21518/2079-701X-2014-9-68-75
Views:
375
Email this article 